Former Medtronic CEO Bill Hawkins Joins Ketryx Board to Solve the AI Bottleneck in Life Sciences

Ketryx, the agentic continuous compliance platform for safety-critical product development, announced today that William A. Hawkins, former Chairman and CEO of Medtronic, has joined its Board of Directors. Hawkins also participated in the company’s Series B financing, signaling strong industry support for Ketryx’s mission to automate compliance in life sciences.

Ketryx helps companies in safety-critical industries, including medical devices, pharmaceuticals, and robotics, accelerate product development by automatically generating compliant documentation, maintaining continuous traceability, and enabling safe and verifiable AI at scale in the tools teams already use. The company’s platform overlays existing tools to automate documentation, create traceability, and accelerate release cycles without disrupting workflows. Ketryx AI Agents reduce manual work by up to 90 percent and help teams identify and close compliance gaps, improving both speed and quality across the product lifecycle.

The appointment of Hawkins, who led Medtronic from 2007 to 2011 and oversaw its growth into a global medical technology leader, underscores the importance of regulatory compliance in the adoption of AI in life sciences. Hawkins’ experience navigating complex regulatory environments will be instrumental as Ketryx expands its platform to address the AI bottleneck that many life sciences companies face when integrating artificial intelligence into their product development processes.

Ketryx is trusted by four of the world's top five medical device manufacturers, according to the company. The platform’s ability to automatically generate compliant documentation and maintain continuous traceability is critical for companies seeking to leverage AI while meeting stringent regulatory requirements. By joining the board, Hawkins will help guide Ketryx’s strategy to further penetrate the market and solve the compliance challenges that slow down innovation.

The Series B financing participation by Hawkins is a vote of confidence in Ketryx’s technology and market potential. The company’s agentic continuous compliance platform is designed to work with the tools teams already use, reducing the need for manual processes and enabling faster release cycles without compromising safety or quality. For more information, visit www.ketryx.com.